- All
- Product Name
- Product Keyword
- Product Model
- Product Summary
- Product Description
- Multi Field Search
Views: 30 Author: Site Editor Publish Time: 2024-05-10 Origin: Site
Query Drug：Avacopan
Query Time：2024-06-04 09:21:05
*** Disclaimer *** The information provided here is sourced from resources such as Drugs.com, the Orange Book, etc., and is auto-generated by the Unibest Digital Center. The content is intended exclusively for pharmaceutical professionals. Unibest does NOT accept legal responsibility for ANY medical actions taken based on this information. ALWAYS consult with your doctor for medical advice. In addition, this product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.
Avacopan (Tavneos) is used to treat two forms of ANCA-associated vasculitis, both granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA). Avacopan is an add-on treatment used with other medicines for adults with active and severe symptoms.
Avacopan works by blocking a receptor in the blood called complement 5a (or C5a), which is part of the immune system. When Avacopan blocks the C5a receptor it may help reduce blood vessel inflammation, improving disease symptoms. Avacopan is called a complement 5a receptor (C5aR) antagonist.
Avacopan FDA approval was received on October 7, 2021, under the brand name Tavneos by ChemoCentryx, Inc. Tavneos is FDA-approved as a treatment for adults with severe active ANCA-associated vasculitis (granulomatosis with polyangiitis and microscopic polyangiitis) when used together with standard therapy including glucocorticoids.
Anti-neutrophil cytoplasmic autoantibody-associated vasculitis (ANCA-associated vasculitis) is a rare autoimmune disease that causes inflammation and damage to small or medium-sized blood vessels, affecting various organs, including airways, kidneys, and lungs. Two forms of ANCA-associated vasculitis are granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA)
Granulomatosis with polyangiitis (GPA), previously called Wegener’s granulomatosis, mainly affects the respiratory tract and the kidneys, leading to sinusitis, nosebleeds, and kidney disease.
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
Source MEDRT
Source: MEDRT
Source MEDRT
Source FDASPL
Source DAILYMED
Source FDASPL
Source DAILYMED
Source FDASPL
Source DAILYMED
[Last update] 2024-05-21
Avacopan's Innovator is CHEMOCENTRYX INC
The unique dosage forms from the innovator include：1. CAPSULE;ORAL.
| Index | Route | Brand Name | Labeler | Approval Date | Dosage |
|---|---|---|---|---|---|
| 1 | CAPSULE;ORAL | TAVNEOS | CHEMOCENTRYX INC | Oct 7, 2021 | 10MG |
This drug still has 4 effective patents.
| Patent Number | Submission Date | Expiration Date | Drug Substance Patent? | Drug Product Patent? |
|---|---|---|---|---|
| 8906938 | Nov 3, 2021 | Dec 21, 2029 | Y | Y |
| 8445515 | Nov 3, 2021 | Feb 3, 2031 | Y | Y |
| 11603356 | Apr 14, 2023 | May 29, 2041 | Y | Y |
| 11951214 | Apr 26, 2024 | Nov 27, 2039 | Y |
The innovator CHEMOCENTRYX INC's portolio contains products with the following 1 API(s)： AVACOPAN
The above products are related to 1 diseases： Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
